2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
作者信息
Singh Jasvinder A, Furst Daniel E, Bharat Aseem, Curtis Jeffrey R, Kavanaugh Arthur F, Kremer Joel M, Moreland Larry W, O'Dell James, Winthrop Kevin L, Beukelman Timothy, Bridges S Louis, Chatham W Winn, Paulus Harold E, Suarez-Almazor Maria, Bombardier Claire, Dougados Maxime, Khanna Dinesh, King Charles M, Leong Amye L, Matteson Eric L, Schousboe John T, Moynihan Eileen, Kolba Karen S, Jain Archana, Volkmann Elizabeth R, Agrawal Harsh, Bae Sangmee, Mudano Amy S, Patkar Nivedita M, Saag Kenneth G
机构信息
University of Alabama at Birmingham.510 20th Street South, Birmingham, AL 35294, USA.
出版信息
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
Abstract
摘要
相似文献
1
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
2
The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.
Arthritis Rheum. 2008 Jun 15;59(6):757-9. doi: 10.1002/art.23723.
3
Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.
Arthritis Care Res (Hoboken). 2013 May;65(5):832. doi: 10.1002/acr.21873.
4
Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622-3; author reply 1623-4. doi: 10.1002/acr.21809.
5
American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al.
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622. doi: 10.1002/acr.21770.
6
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721.
7
Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.
Arthritis Care Res (Hoboken). 2012 May;64(5):648-51. doi: 10.1002/acr.21659.
8
Reply: To PMID 22473917.
Arthritis Care Res (Hoboken). 2013 May;65(5):832-3. doi: 10.1002/acr.21872.
9
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Arthritis Rheumatol. 2017 Aug;69(8):1538-1551. doi: 10.1002/art.40149. Epub 2017 Jun 16.
10
Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis.
Am J Manag Care. 2014 May;20(7 Suppl):S136-44.
引用本文的文献
1
A Review of the Current Clinical Aspects of Sjögren's Disease: Geographical Difference, Classification/Diagnostic Criteria, Recent Advancements in Diagnostic Methods, and Molecular Targeted Therapy.
J Clin Med. 2025 Aug 7;14(15):5577. doi: 10.3390/jcm14155577.
2
Pharmacogenomics of TNF inhibitors.
Front Immunol. 2025 May 21;16:1521794. doi: 10.3389/fimmu.2025.1521794. eCollection 2025.
3
Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study.
RMD Open. 2025 Apr 20;11(2):e005247. doi: 10.1136/rmdopen-2024-005247.
4
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment.
Front Med (Lausanne). 2025 Mar 28;12:1512501. doi: 10.3389/fmed.2025.1512501. eCollection 2025.
5
Management of IgG4-related cholangitis: diagnosis, therapy, and long-term surveillance.
Gastroenterol Rep (Oxf). 2025 Apr 4;13:goaf032. doi: 10.1093/gastro/goaf032. eCollection 2025.
6
Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: why screening still matters.
Clin Rheumatol. 2025 Apr;44(4):1851-1859. doi: 10.1007/s10067-025-07350-x. Epub 2025 Feb 25.
7
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records.
Rheumatol Adv Pract. 2024 Dec 14;9(1):rkae140. doi: 10.1093/rap/rkae140. eCollection 2025.
8
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study.
Rheumatol Ther. 2024 Dec;11(6):1629-1648. doi: 10.1007/s40744-024-00719-5. Epub 2024 Nov 1.
9
Application of disease activity index in rheumatoid arthritis management in Korea.
J Rheum Dis. 2024 Oct 1;31(4):193-199. doi: 10.4078/jrd.2024.0077. Epub 2024 Aug 2.
10
Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018-2021.
J Clin Tuberc Other Mycobact Dis. 2024 Jun 22;36:100460. doi: 10.1016/j.jctube.2024.100460. eCollection 2024 Aug.
本文引用的文献
1
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Cochrane Database Syst Rev. 2011 Feb 16(2):CD007649. doi: 10.1002/14651858.CD007649.pub2.
2
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
Arthritis Rheum. 2011 Mar;63(3):573-86. doi: 10.1002/art.30129.
3
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584.
4
Tocilizumab for rheumatoid arthritis.
Cochrane Database Syst Rev. 2010 Jul 7(7):CD008331. doi: 10.1002/14651858.CD008331.pub2.
5
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
Ann Rheum Dis. 2010 Jun;69(6):964-75. doi: 10.1136/ard.2009.126532. Epub 2010 May 5.
6
Golimumab for rheumatoid arthritis.
Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD008341. doi: 10.1002/14651858.CD008341.
7
Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007848. doi: 10.1002/14651858.CD007848.pub2.
8
Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
Ann Rheum Dis. 2009 Jul;68(7):1153-8. doi: 10.1136/ard.2008.093294. Epub 2008 Oct 17.
9
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.
Arthritis Rheum. 2008 Oct 15;59(10):1467-74. doi: 10.1002/art.24106.
10
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
Lancet. 2008 Aug 2;372(9636):375-82. doi: 10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.
Zotero 插件